enzyme bilirubin UDPglucuronate glucuronyltransferase of rat liver in competition with UDPglucuronic acid, the donor in glucuronide formation. Inhibition. is thus more pronounced at low UDPglucuronic acid concentrations (Adlard & Lathe 1970a) . (3) Concentrations of UDPglucuronic acid are low in newborn and feetal guinea-pig liver (Dutton 1959 , Flodgaard & Brodersen 1967 and in human fcetal liver (Dutton 1959) . (4) Newborn serum, newborn urine and liquor amnii contain substances which inhibit the secretion of conjugated bilirubin from rat liver slices (Holton & Lathe 1963; Adlard & Lathe 1969, unpublished results) .
Jaundice occurring in certain infants in association with breast feeding has been ascribed to the presence of 5B-pregnane-3a,20p-diol in the maternal milk (Arias et al. 1964) . Although the occurrence of this steroid in milk has been confirmed (Krauer-Mayer et al. 1968 ), the hypothesis that it is the cause of breast-milk jaundice is questioned in view of the failure of this steroid to inhibit bilirubin glucuronide formation by human liver in vitro (Adlard & Lathe 1970b Following myocardial infarction, hyperglycemia is a frequent accompaniment of the low cardiac output state associated with cardiogenic shock (Ellenberg et al. 1952 , MacKensie et al. 1964 , Taylor et al. 1969 . The rise in blood sugar at the onset of the shocked state is predominantly due to the increased glycogenolysis resulting from the large increase in sympathetic stimulation that is an integral part of the shock syndrome (Valori et al. 1967 , Aleksandrow et al. 1967 , Jewitt et al. 1969 . However, the hepatic stores of glycogen are relatively small and whilst increased gluconeogenesis resulting from increased secretion of adrenocortical steroids (Logan & Murdock 1966) may play a role in repletion of these stores, the persistence of hyperglyc0mia must implicate a failure of tissue uptake of glucose. This may be due to a number of factors, including (1) a failure of insulin secretion in response to the hyper-glyc0mic stimulus; (2) the acute development of circulating anti-insulin factors; (3) increase in tissue resistance to insulin and/or glucose uptake. The first hypothesis was tested by measuring the insulin secretion response serially in 5 male patients in cardiogenic shock following myocardial infarction, in 12 male patients with uncompli- (Saxton et al. 1971 ). The patients in circulatory WRhck all had a systolic blood p ure below 100 mmHun and all had cinical evidc of severe sympathetic overactivity, with pale, cold, sweating skin, anuria and mental restessness, apathy or confusion. In all the PaO, was lSs than 60 mmHg, and the systemic artial pH less than 7.37. In all 5 of the shocked patients Xt ins8ulin secretion respons to intravenous tqilnutamide was severely ( Fig 1) . One paient died a few hours later and patet T J diWd on tie trd day from a fute inyoc alinfateton, nhe 4 patients in whom serial studies w'(min chiling patient T J on days 1' and 2) the rapid clinical improvement was W by a similar improen_ t in inlin s on pones (Fig 2) .: None of the patiens with uncomplicted myocardial infarction showed an abnormal insulin secrtion response -to to (Fig 3) . It was therore concludedthA the o in the plasa insun to the stis of intavenous taolutamide was an intal part of the shock syndrome following myocardial infarction.
Two further problems were immediately posed.
Were other forms of severe heart failure associated with suppression of inslin secretion? What were the mechanism involved?
The first problem was investigatd by measuring the insulin section response in sever heart failure due to two different causes: aoute low cardiac output syndrome following o9en4heut surgry; seve chrnic heart failr due to vavular heart disae. ne low cdiac output syndrome following extensive open-heat surgery s in many circulatory respects the shock syndrome following myocardial infarction. Six patients n open-heart surgery for advad vahr heart disease were studied; their dikl and lboratory details have been published In full elwhre ). Insulin s tsts we performed the day before o ationa srially on days l, 2, 3, 5, 7, 14 and 28 wr o .AI l patients were clinicaly well and whoutcpngs-n tive heart failure before operation; at thiis the insulin secretion response to In us tamide was normal in all. Folwing o ion 3 patients made a rapid and uninterrupted recovery and in all the insulin secretion response remained within normal limits throughout the post-operative period. In 3 patients the low cardiac output syndrome developed immediately after oprion. The onst of tris low flw st was accompanied by a severe suppression in insulin secretion which only improved with the gradual improvement in clinical state over the succeeding days (Fig 4) . These findings suggest that suppression of insulin secretion is an accompaniment of severe acute heart failure due to spontaneous myocardial infarction or open heart surgery.
To examine the possibility that the suppression of insulin secretion also may accompany other forms of severe heart failure, 8 patients in severe chronic heart failure due to valvular heart disease were studied. All had been in severe congestive heart failure for many months and were considered to be in the terminal phase of their illness. Their full personal, clinical and laboratory details have been published elsewhere (Sharma et al. 1970) . In all 8 patients the insulin secretion response to intravenous tolbutamide was greatly impaired (Fig 5) . All patients were then treated with twice-daily intravenous injections of aminophylline combined with frusemide whilst conventional treatment with oral digoxin, frusemide and I z 0 potassium was continued. In spite of this intensive treatment 2 patients died. At the end of four weeks' treatment the insulin secretion test was repeated in the remaining 6 patients. Three patients had made a significant, if incomplete, clinical improvement. In all 3 the clinical improvement was accompanied by a significant increase in the insulin secretion response (Fig 6) . The clinical improvement in the other 3 patients was much less and the concomitant improvement in insulin secretion response was similarly limited. Thus, suppression of insulin secretion is an accompaniment of chronic as well as acute heart failure.
Two mechanisms probably predominate in the suppression of insulin secretion in patients with acute severe heart failure: reduced pancreatic blood flow; increased sympathetic activity and secretion of catecholamines. In circulatory shock or any other severe heart failure, the redistribution of regional blood flow results in a considerable reduction in splanchnic and pancreatic blood flow (Selkurt et al. 1947 , Levy 1958 , Gregg 1962 ). This in turn may reduce insulin secretion by attenuating the stimuli to insulin secretion or by secondarily affecting the metabolism of the islet B cells of the pancreas. Although there is little or no direct experimental evidence on these important points, there is a much greater volume of evidence on the role of the sympathetic nervous system in the control of insulin secretion. Loubatieres et al. (1965) observed that small amounts of adrenalirne and noradrenaline infused into the pancreatic artery of the dog resulted in histological changes confined to the beta-cells; sympathetic blockade with dihydroergotamine completely protected the beta-cells against these changes.
Catecholamines have been shown to inhibit insulin release both in animals (Altszuler et al. 1967 ) and in man (Porte et al. 1966 ) and alphaadrenergic blocking drugs reverse this inhibition (Porte 1969) . Therefore it was decided to explore more fully the role of the sympathetic nervous system in the control of insulin secretion with par- ticular respect to the therapeutic application of these findings to patients in heart failure. The detailed design of this study has been reported elsewhere . Serial studies in normal subjects confirmed that adrenergic alphareceptor blockade with phentolamine and betareceptor stimulation with isoprenaline both produced significant and large increases in the insulin secretion response to intravenous tolbutamide. Conversely alpha-stimulation with methoxamine and beta-blockade with propranolol both resulted in a significant suppression of insulin secretion (Fig 7) . In patients in severe heart failure the suppression of the insulin secretion response to intravenous tolbutamide was rapidly reversed with either phentolamine or isoprenaline (Fig 8) . Parasympathetic stimulation or blockade had no measurable effect on the insulin secretion response. These observations suggest that the sympathetic nervous system plays an important role in determining the facility with which stimuli such as glucose or tolbutamide are able to release insulin from the pancreas. When sympathetic drive is increased by severe heart failure, the normal stimuli to insulin secretion may be overridden. Under these conditions alpha-receptor blockade with phentolamine or beta-receptor stimulation with isoprenaline may rapidly reverse such suppression.
Summary
The normal insulin secretion response to intravenous tolbutamide has been found to be suppressed in patients with severe power failure of the heart whether this be due to cardiogenic shock following myocardial infarction, pumping failure following open-heart surgery or severe congestive heart failure due to valvular heart disease. Two mechanisms are probably responsible for this insulin suppression: low pancreatic blood flow due to redistribution of the cardiac output; increased activity of the sympathetic nervous system. In normal subjects adrenergic alphareceptor stimulation and beta-receptor blockade significantly depressed the insulin secretion response to tolbutamide. Alpha-blockade with phentolamine and beta-stimulation with isoprenaline significantly increased the insulin secretion response both in normal subjects and in patients with heart failure. It is concluded that the sympathetic nervous system has an important and sometimes overriding role in the control of insulin secretion, particularly in the presence of severe or acute heart failure.
